ShockWave Medical Inc. (NASDAQ:SWAV) stock’s Relative Strength Index (RSI) is 66.61, with weekly volatility at 3.79% and ATR at 1.93. The SWAV stock’s 52-week price range has touched low of $22.01 and a $50.90 high. Its shares traded higher over the last trading session, gaining 2.65% on 07/29/20. The shares fell to a low of $46.9387 before closing at $49.26. Intraday shares traded counted 0.35 million, which was 14.19% higher than its 30-day average trading volume of 405.40K. SWAV’s previous close was $47.99 while the outstanding shares total 31.64M.
Investors have identified the Medical Devices company ShockWave Medical Inc. as an interesting stock but before investments are made there, an in-depth look at its trading activities will have to be conducted. The share is trading with a market value of around $1.65 billion, the company now has both obstacles and catalysts that affect them and they came from their mode of operations. With the company affected by events currently, it is a perfect time to analyze the numbers behind the firm in order to come up with a rather realistic picture of what this stock is.
ShockWave Medical Inc. (SWAV) Fundamentals that are to be considered.
When analyzing a stock, the first fundamental thing to take into account is the balance sheet. How healthy the balance sheet of a company is will determine if the company will be able to carry out all its financial and non-financial obligations and also keep the faith of its investors. For SWAV, the company has in raw cash 123.11 million on their books with 0.79 million currently as liabilities. How the trend is over time is what investors should be concerned about. The company has a healthy balance sheet as their debt profile has been on an incline. In terms of their assets, the company currently has 197606000 million total, with 18763000 million as their total liabilities.
SWAV were able to record -28.84 million as free cash flow during the third quarter of the year, this saw their quarterly net cash flow reduce by -15.93 million. In cash movements, the company had a total of -24.19 million as operating cash flow.
Potential earnings growth for ShockWave Medical Inc. (SWAV)
In order to determine the future investment potential for this stock, we will have to analyze key trends that affect it. During the third quarter of the year, ShockWave Medical Inc. recorded a total of 15.2 million in revenue. This figure implies that they witnessed a quarterly year/year change in their earnings with 52.17% coming in sequential stages and their sales for the third quarter increasing by 5.82%.
What matters though is how it ends. When the core data for the company is broken down, then the stock sounds interesting. The company spent 5.65 million trying to sell their products during the last quarter, with the result yielding a gross income of 9.55 million. This allows shareholders to hold on to 31.64M with the revenue now reading -0.59 cents per share. This is a figure that is close to analyst’s prediction for their fourth quarter (-0.48 cents a share).
Having a look at the company’s valuation, the company is expected to record -2.14 total earnings per share during the next fiscal year. It is very important though to remember that the importance of trend far outweighs that of outlook. This analysis has been great and getting further updates on SWAV sounds very interesting.
Is the stock of SWAV attractive?
In related news, Chief Commercial Officer, Zacharias Isaac sold 4,000 shares of the company’s stock in a transaction that recorded on Jul 10. The sale was performed at an average price of 43.19, for a total value of 172,772. As the sale deal closes, the Director, Papiernik Antoine now sold 29,729 shares of the company’s stock, valued at 1,391,020. Also, Chief Commercial Officer, Zacharias Isaac sold 4,000 shares of the company’s stock in a deal that was recorded on Jun 10. The shares were price at an average price of 46.89 per share, with a total market value of 187,560. Following this completion of acquisition, the 10% Owner, Sofinnova Capital VII FCPR now holds 29,729 shares of the company’s stock, valued at 1,391,020. In the last 6 months, insiders have changed their ownership in shares of company stock by 1.70%.
4 out of 6 analysts covering the stock have rated it a Buy, while 2 have maintained a Hold recommendation on ShockWave Medical Inc.. 0 analysts has assigned a Sell rating on the SWAV stock. The 12-month mean consensus price target for the company’s shares has been set at $50.00.